Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Witnesses say FDA bottlenecks helped fuel illicit e‑cigarette market from overseas
Loading...
Summary
Industry experts and lawmakers told the Oversight Committee the FDA’s premarket tobacco application process and slow authorizations left demand unmet, enabling large flows of illicit disposable e‑cigarettes — largely from China — into U.S. markets, including products popular with youth.
Lawmakers and witnesses at a House Oversight hearing blamed the Food and Drug Administration’s approach to authorizing e‑cigarettes for creating conditions that allowed a large illicit market to take root.
Guy Bentley, Director of Consumer Freedom at the Reason Foundation, told the committee that regulatory bottlenecks around the FDA’s premarket tobacco product application (PMTA) pathway have blocked a regulated supply of safer nicotine alternatives. “Since 2019, illicit products have flooded the market with almost 90% of e‑cigarettes being sold illegally, mainly consisting of disposable products from China,” Bentley said.
Nut graf: Panelists argued the agency’s slow or opaque authorization process left adult demand unmet and discouraged legitimate U.S. manufacturers while overseas suppliers filled the gap. They recommended process reforms and stepped-up enforcement at ports.
Bentley and other witnesses said the FDA has authorized only a small fraction of vaping products — far fewer than combustibles — and that the agency’s “appropriate for the protection of public health” evaluation has been applied in a way that reduces the number of authorized products. Bentley told the committee the result is a regulated market that is small compared with consumer demand, and an illicit market that is unaccountable and often opaque in its ingredients.
Members pressed witnesses on enforcement and border control. Bentley acknowledged a multi‑agency task force exists involving DOJ and Customs and Border Protection, but said task forces are insufficient without internal regulatory reform. “This is just a bandage unless its own internal processes can be reformed,” he said.
Rep. Donald displayed a sample disposable device and asked whether consumers can know the contents of such products; Bentley said consumers generally do not know what illicit products contain and that legitimate U.S. firms have struggled to obtain authorizations.
Ending: Members on both sides signaled interest in policy changes to speed legitimate product review and to increase enforcement at ports and retail locations. Several suggested outreach to FDA on procedural changes for PMTA review times and transparency.
